Wordt geladen...
Developing treatments for pulmonary arterial hypertension
Developing new treatments for pulmonary arterial hypertension (PAH) is a challenge. We have enjoyed success with regulatory approvals for three drug classes—prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. But we have also seen some disappointing results, for exa...
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Medknow Publications & Media Pvt Ltd
2013
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3641724/ https://ncbi.nlm.nih.gov/pubmed/23662193 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2045-8932.109961 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|